Oncolytic Virus Immunotherapy |
Autore | Marchini Antonio |
Pubbl/distr/stampa | Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 |
Descrizione fisica | 1 electronic resource (366 p.) |
Soggetto topico |
Medicine
Clinical & internal medicine |
Soggetto non controllato |
oncolytic viruses
melanoma immunotherapy checkpoint inhibitors combinatory therapy reovirus oncolytic virus adenovirus oncolytic virotherapy targeting immunogenic cell death αvβ6 integrin oncolytic adenovirus cancer immunotherapy multi-stage immunostimulatory arming HSV-1 clinical trials newcastle disease virus NDV cancer immune checkpoint inhibitor PD-1 PD-L1 CTLA-4 type I interferon herpes simplex virus retargeted virus tropism retargeting tumor checkpoint inhibitor vaccination antigen-agnostic vaccination HER2 parvovirus tumor microenvironment combination therapy glioblastoma pancreatic cancer colorectal cancer measles virus vector engineering immune checkpoint blockade antitumor immune response delivery genetic modification biomarkers personalized oncolyticvirotherapy class I HLA immunosurveillance immunoediting oncogenic signaling RAS DNA methyltransferase inhibitor (DNMTi) viral mimicry epigenetic silencing adoptive T cell therapy CAR T cell pancreatic ductal adenocarcinoma vesicular stomatitis virus small molecule cancer immune therapy cancer therapy |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910566462203321 |
Marchini Antonio
![]() |
||
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Targeting STAT3 and STAT5 in Cancer |
Autore | Moriggl Richard |
Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
Descrizione fisica | 1 electronic resource (578 p.) |
Soggetto topico |
Research & information: general
Biology, life sciences |
Soggetto non controllato |
multiple myeloma
STAT3 S3I-1757 nanoparticle CD38 siRNA/RNAi polyethylenimine PEI lipopolyplex siRNA delivery glioma glioblastoma STAT5 AKT ERK1/2 prolactin androgens prostate cancer knockout escape mechanisms stem/progenitor cells cell hierarchy cancer CD4+ T cells CD8+ T cells myeloid cells immune check point hepatitis C virus (HCV) cirrhosis hepatocellular carcinoma (HCC) endoplasmic reticulum (ER) stress oxidative stress (OS) unfolded protein response (UPR) microRNA-122 (miR-122) nuclear factor erythroid 2-related factor 2 (NRF2) signal transducer and activator of transcription 3 (STAT3) hepatocyte nuclear factor 4 alpha (HNF4A) solid cancers cell cycle apoptosis inflammation mitochondria stemness tumor suppression melanoma autoimmune disease immunotherapy tumor-immune cell interactions breast cancer PD-L1 M2 macrophages NK cells STAT3 inhibitor XIII hedging transaction costs dynamic programming risk management post-decision state variable cancer progression cancer-stem cell cytokine therapy resistance metastasis immunosuppression tumor microenvironment proliferation tyrosine kinase 2 JAK family of protein tyrosine kinases signal transducer and activator of transcription cytokine receptor signaling gain-of-function mutation tumorigenesis ADAM17 interleukin-6 trans-signaling epidermal growth factor receptor (EGF-R) shedding metalloprotease tumor necrosis factor alpha (TNFα) inflammation associated cancer colon cancer lung cancer SH2 domain mutations autosomal-dominant hyper IgE syndrome inflammatory hepatocellular adenomas T-cell large granular lymphocytic leukemia T-cell prolymphocytic leukemia growth hormone insensitivity syndrome nuclear pore complex nuclear transport receptors nucleocytoplasmic shuttling targeting tumor-associated macrophages adoptive T cell therapy immune suppression STAT transcription factors JAK STAT T-PLL T-cell leukemia meta-analysis STAT5B signaling small-molecule inhibitors cancer models companion animals comparative oncology pharmacological inhibitor STAT5 signaling chemotherapy resistance myeloid leukemia heat shock proteins chaperones stabilization targeted therapy ovarian cancer hematopoietic cancers therapeutic targeting pharmacological inhibitors mTOR Bone Marrow Failure Syndromes lymphocytes lymphoma T-cells RHOA NGS MPN JAK2 V617F neoplastic stem cells |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910557623503321 |
Moriggl Richard
![]() |
||
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|